Case File
efta-02572697DOJ Data Set 11OtherEFTA02572697
Date
Unknown
Source
DOJ Data Set 11
Reference
efta-02572697
Pages
6
Persons
0
Integrity
Extracted Text (OCR)
Text extracted via OCR from the original document. May contain errors from the scanning process.
From:
Jeffrey Epstein <[email protected]>
Sent:
Saturday, August 10, 2013 12:16 PM
To:
Barrett, Paul S
Subject:
Re: FW: The J.P. Morgan View : What countries to buy or sell
ok
On Sat, Aug 10, 2013 at 5:37 AM, Barrett, Paul S
> wrote:
Jeffrey
I think we should add another 2mm to that European equity basket. We went f=rther overweight Europe.
Paul Barrett I Managing Director I Global Investment Opportunities Group I =.P. Morgan Private Bank I
Original Message
From: Perlman, Daniel A
Sent: Friday, August 09, 2013 05:09 PM Eastern Standard Time
To:
Subject: The J.P. Morgan View : What countries to buy or sell
Global Asset Allocation
The J.P. Morgan View: What countries to buy =r sell
Click here for =he full Note and disclaimers.
EFTA_R1_01742400
EFTA02572697
•
Asset allocation ** An increasing part of our allocation exposure is now in country choi=es. We raise our
European overweight, and are considering at what point we=need to cut our EM underweight vs. Japan.
•
Economics •• Data are tracking the expected rebound in Global GDP growth, with ba=anced risk. But we
are seeing increasing signs of a rebound in manufacturi=g. Europe Q2 is raised to 1%, but Russia and Mexican growth
forecasts for =013/14 are cut.
•
Fixed Income" Bond duration should be traded on local conditions: short in US, Eur= area and EM; long
in Japan and Australia, neutral in the UK.
•
vs. EM.
range.
Equities •• Open a Cyclical vs. Defensive sector overweight globally. Cut by hal= the overweight in Japan
Credit • * OW financials vs. non financials and Europe vs. the US.
FX • • We resist the rise in GBP and EUR vs. USD and expect them to fall ba=k again within this year's
Commodities ** Take profit on OW energy vs. base metals and open an outright long i= energy.
•
Click her= for video. <http://emaillink.jpmorgan.com/t=AQ/AAMGjA/AAYLOg/O1FDJA/Ael/ABWW-
Q/AQ/VEul>
•
Our top investment recommendation remains =o be aggressively overweight equities versus cash and
fixed income. But b=yond that, we have concentrated much of our tactical risk on country and r=gional allocations. How
do we allocate here? What is working, or not worki=g? And where are we considering change?
•
Our top regional allocation has been to underweight EM against DM across asset classes. The rationale
has be=n predominantly fundamental in that we and the consensus have been forced =o steadily lower our growth
expectations in EM, outright and relative to D=. We do not yet have reason to change this assessment. The past few
weeks of lower EM PMIs and the weak t=acking of Q3 activity data versus forecasts leave us with further downside=risks
on EM growth projections.
•
This week alone, we cut Mexico and Russia.=EM policy makers on average will likely not provide much
support, in some =ountries because inflation remains too high, and in others because capital=outflows have put
downside pressure on the currency that is preventing their central banks from easin= rates. In addition, as reviewed in
Job gains to lag global growth lift, Kasman et al., July 24, we see =ailing EM profit margins, in response to tight labor
markets and rising wa=e costs, also depressing EM growth.
•
That said, we will not remain underweight =M forever, as relative value is getting re-established, many
active invest=rs are already UW, and at some point, the rebound in DM should pull EM out=of its funk. This week's data
dump from China is providing support for our projected rebound in gro=th from Hl*s 6.5% to 7.5% in H2. EM equities
are still underperforming t=is week, but at a slower pace now. EM is holding itself vs. DM in credit a=d FX over the past
month.
•
We think it too early to move back to OW E= asset classes, given still downside risk on EM forecasts, and
are instead=trimming UWs selectively, especially in fixed income and FX.
•
Our European overweight is working =icely and is getting good support from economic data. This week
alone prov=ded upside surprises on economic activity data, allowing us to raise Q2 to=1% in the Euro area. The
challenge we all face on Europe, after years of crisis and recession, =s whether the rebound is a *dead cat bounce*, born
2
EFTA_R1_01742401
EFTA02572698
from a relief that =urope is at least not blowing up this year, or whether we can see Europe o=fering good value and
economic upside over the more medium term.
*
We are somewhere in the middle here, seein= the rebound a reflection of more rational policy making
(more monetary po=icy support and a move from destructive austerity) and progress towards re=ucing EMU North
South imbalances. Wage cost gaps between the core and periphery are shrinking an= the periphery's current account
deficit has virtually disappeared. The =urrent quiet in euro financial markets, supported by the OMT and ESM, coul= thus
last for years. We note that this does not mean that Europe will become an economic locomotive, as supp=y-side
economics and macro stimulus are sorely missing. Overall, with a co=tinued absence of a funding crisis, relative value
and client flows will d=ive performance, in our view. We stay overweight European equities relative to EM, and credit
against the U=, as the great rotation has arrived in the US, but not in Europe.</=>
"
We have been overweight Japanese eq=ities versus EM since Nov of last year, to position for Japanese
reflation= This has performed well, but has lost money over the past month, as econo=ic data have started to disappoint
against our quite bullish expectations. We cut 2013 Japan gr=wth from 2.2% to 2.0% today, and in GMOS this week took
half profit on our OW. This is largely position =anagement as we remain long-term bullish on Japanese reflation and
equitie=.
Fixed l=come
•
Bond yields followed equity markets down t=is week. Globally, we retain a bearish bias on bonds, but do
not see this =s a structural short as the expected rise in yield is likely to remain une=en, and highly variable by country.
•
In the US, we retain a bearish bias on mom=ntum, the start of tapering next month, and evidence of
investors switchin= broadly from fixed income to equities. We continue to execute this view b= selling the belly of the
curve 5s against l0s and 2s. In euros, we stay short 10-year Bunds on =teadily improving economic data. In sterling, the
move to rate guidance by=the BoE if anything increases uncertainty and we move from bullish to neut=al. And in Japan,
we remain positive duration. In Australia, we stay bullish as the RBA has further room to eas=. We stay bearish in local
EM bonds.
Equitie=
*
The prospective rebound in global manuf=cturing is inducing us to open an overweight in Cyclical vs.
Defensive=equity sectors globally. Both our US and European equity strategists are c=rrently favoring Cyclical sectors.
•
It is true that the global manufacturing P=I has not yet staged a convincing rebound. But our economists
are confiden= of a manufacturing rebound in the coming months, driven initially by DM e=onomies but also pulling EM
economies along on the way up. China's July activity indicators are a=ding conviction to this view.
•
Is this is a reason to reverse our EM equi=y underweight? We do not think so. We think that a better trade
to position for a rebound in global manufac=uring is via a Cyclical vs. Defensive sector overweight rather than an EM =s.
DM equity overweight. This is because the driver of this manufactur=ng rebound emanates from within DM rather than
EM.
*
Are depressed valuations a good reason =o buy EM equities? We do not think so, either. It is true that the
PE gap between=MSCI World and MSCI EM indices has been widening for two years now to well=above historical
averages, 3.8 pts currently vs. a historical average of 2=7. This 3.8pt gap is above average but not exceptionally high as
shown in the chart above. Gaps=of this magnitude could have been used as an argument to buy EM equities a= the
beginning of the year or in 1995/1996, but that would have proved a d=sastrous bet. In addition, the valuation gap
between EM and DM equities narrows if one adjusts for the hi=her weight of commodity sectors in EM which typically
trade at a lower mul=iple than other sectors.
3
EFTA_R1_01742402
EFTA02572699
*
This is not to say that value is not usefu=. We do believe that value combined with a positive fundamental
change pro=ides a good reason to overweight a region or sector. And this is why we in=tead overweight Europe in our
regional portfolio.
*
Japanese equities have stopped outperfo=ming. We reduced our overweigh= in Japanese vs. EM equities
in our model portfolio in this week's GMOS. There is currently no policy impetus and the positive economic=news is
largely priced in. In addition, CFTC spec positions on Nikkei are =rifting lower, suggesting that overseas investors have
started taking prof=t on the Japanese equity trade.
Credit<=span>
*
US Financials have outperformed Non=F inancials recently and are now only 1 lbp wider in spread, close to
the 8b= multi-year tight reached in May. We expect continued Financials outperfor=ance due to stronger fundamentals,
the recovery in Europe, and the deterioration of some non-Fi=ancial sectors driven by commodity trends, competitive
environment and sha=eholder friendly activity (CMOS, Eric Beinstein et al., Aug 9). We =re OW both US and European
financials in our GMOS portfolio.
•
In Europe, the improved economic ou=look and continued strong demand for quality spread product are
strong pos=tives. At this point, we see more upside on our European growth forecasts =han in the US. In addition, as we
argued in last week's Flows & Liquidity, Who is driv=ng the great rotation?, Aug 2, US investors are moving from fixed
inco=e into equities but we are not seeing this rotation in Europe, giving supp=rt for euro spread product relative to the
US market. Euro spreads used to trade well below US spreads before the=great recession (see chart on the right) and
with some form of normality r=turning to the Euro area, we think there is reason to believe that euro sp=eads will again
trade well below US spreads.
Foreign=Exchange
*
With US 10-yr yields side-winding around 2=6% for almost two months and FX volumes down to their
typical August lows,=the dollar index is freefalling. The trade-weighted currency (JPMQUSD) has=declined for four of the
past five weeks, and while moves have been inconsistent across pairs, =ome of this year's biggest losers (JPY, GBP, NZD,
NOK, ZAR) have becom= this month's biggest gainers. When the dollar was rallying in late spri=g it seemed
unreasonable to expect the move to be so broad and persistent throughout 2013, since that view assume= that only the
US economy would perk up in Q2/Q3. Instead, selective USD s=rength has been our message for months. Now that the
dollar is collapsing =n a number of crosses, it also seems hasty to extrapolate. The baseline view this fall for a higher US=
vs Asia and some commodity currencies (AUD, ZAR) is unchanged, even w=th better Chinese data. If China only manages
to stabilize but US rates he=d higher this fall, commodity FX like AUD will probably decline.
*
The euro and sterling have bounced 3% over=the past month, moves which are middle-of-the-pack
globally but nonetheles= surprising given the forward guidance the ECB and BoE premiered or previe=ed on July 4. Since
these banks were unveiling guidance in the context of economies exiting recessio= (Euro area) or sub-trend growth (UK),
and since US rates seemed headed hi=her, our view then was that rate guidance would weaken EUR and GBP within
=heir ranges but strengthen some Central European currencies like PLN. What explains EUR and GBP's rise= Growth
surprises, mainly. More Euro area and UK releases than US ones h=ve been beating expectations since May, despite a
few high-profile beats i= the US like Q2 GDP and PMIs/ISMs. And since bond markets tend to move as much on data
momentum as they do on cen=ral bank policy, forward guidance may only be relevant once the consensus =evelops a
more realistic view on European/UK growth, or until US data exhi=it more consistency. Unless we have seriously
misjudged the likelihood of a US acceleration this fall as =iscal drag fades, or unless we have underestimated the ability
of Europe t= deliver above-trend growth for a few quarters, EUR/USD and GBP/USD should=revert lower by a few cents
but remain within this year's range.
Commodi=ies
4
EFTA_R1_01742403
EFTA02572700
*
We have been OW energy vs. base metals<=b> since early April on downside risk in China while we
expected more upsi=e in oil, given tighter supply conditions and Middle East risk. This week =as brought two significant
upside surprises in the Chinese economic data, trade and IP. Additionally,=our metals strategists expect an acceleration
in physical metal demand fro= here due to better Chinese end user demand (see Metals Monthly: China likely to lift
metals in 2H2013, Kaneva et al.= Jul 31). These two data points are not yet enough to create upside risk o= our Chinese
GDP growth forecast, but they do remove a lot of the downside=and given that metal prices are close to production
costs, we think risks are probably more balanced now. =ur position is up some 10% since inception and we now take
profit. We also close our UW in base metals in our GM=S long/only portfolio, leaving us OW energy vs. precious metals.
*
We open an outright long in energy in our long/short portfolio as we still th=nk there is some upside risk
in oil from here given improving US and Europ=an demand coupled with significant supply uncertainty in the Middle East
(=ee Commodity Markets Outlook and Strategy, Colin Fenton, Aug 8). Additi=nally, tight supplies in energy have caused
spot prices to be persistently=higher than forwards, something we expect to continue. This backwardation =f the curve
(downward sloping) is currently pricing a more than 1% a month return from holding the front =ontract and rolling down
into the second each month. This equates to over =2% a year only in roll/slide.
Jan Loeys <http://=maillink.jpmorgan.com/t/AQ/AAMGjA/AAYLOg/QIFDJA/Ael/ABuQqw/AQ/BEeu>
(1-212) 834-5874 <tel:%281-212%29%20834-58=4>
John Normand <http://=maillink.jpmorgan.com/t/AQ/AAMGjA/AAYLC/g/QIFDJA/Ael/A8QyhQ/AWGNvy>
(44-20) 7134-1816
Nikolaos Panigirtzoglou <http://=maillink.jpmorgan.com/t/AQ/AAMGjA/AAYUDg/QIF0JA/Ael/ABQyhg/AQ/Z+BI>
(44-20) 7134-7815
Seamus Mac Gorain <http://rmaillinkjomorgan.com/t/AWAAMGjA/AAYMg/QIFDWAel/A8Qyhw/AQ/Ry8m>
(44-20) 7134-7761
Matthew Lehmann <http://=maillink.jpmorgan.com/t/AO/AAMGjA/AAYLCIg/QIFDJA/Ael/ABlayiA/AQ/uY4e>
=/b>
If you no longer wis= to receive these e-mails then click here to unsubscribe
chttp://emaillink.jornorgan.com/t/AWAAMGjA/AAYMg/QIFDWAel/ABYa=Q/AQ/XLH-> </=>
www.jpmorganmarkets.com
<http://emaillink.jpmorgan.com/t/AQ/AAMGjA/A=YLCIg/OJFDJA/Ael/ABPpLw/AQ/ND4r>
Analyst certificatio=: I certify that: (1) all of the views expressed in this research accurate=y reflect my personal
views about any and all of the subject securities or issuers; and (2) no part of my compensation was, is, or will be directl=
or indirectly related to the specific recommendations or views expressed =erein. Important disclosures, including price
charts, are available for co=pendium reports and all J.P. Morganscovered companies by visiting
https://mm.jpmorgan.com/disclosures/company
<http://emaillink.jpmorgan.com/t/AQ/AAMGjA=AAYLQg/QIFDJA/Ael/gYY/AQ/KSnl> , calling 1-800-477-0406 <tel:1-8=0-
5
EFTA_R1_01742404
EFTA02572701
477.0406>, o= e-mailing [email protected]
chttp://emaillink.jpmorgan.com/t/AQ/AAMGjA/AAYLQg/QIFDJA/Ael/gYc/=Q/D70D> with your request. J.P. Morgres
Strategy, Technical, and Quantitative Research teams may screen comp=nies not covered by J.P. Morgan. For important
disclosures for these compa=ies, please call 1.800.477.0406 <tel:1-800.477.0406> or e-mail
[email protected]
<http://emaillink.jpmorgan.com/t/AQ/AAMGjA/AAYLQg/OJFDJA/=el/gYc/AQ/D70D> .
J.P. Morgan does and=seeks to do business with companies covered in its research reports. As a =esult, investors
should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors
shoul= consider this report as only a single factor in making their investment d=cision.
Confidentiality and =ecurity Notice: This transmission may contain information that is privileg=d, confidential,
legally privileged, and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are
hereby noti=ied that any disclosure, copying, distribution, or use of the information =ontained herein (including any
reliance thereon) is STRICTLY PROHIBITED. A=though this transmission and any attachments are believed to be free of
any virus or other defect that migh= affect any computer system into which it is received and opened, it is th=
responsibility of the recipient to ensure that it is virus free and no re=ponsibility is accepted by JPMorgan Chase & Co.,
its subsidiaries and affiliates, as applicable, for any l=ss or damage arising in any way from its use. If you received this
transmi=sion in error, please immediately contact the sender and destroy the mater=al in its entirety, whether in
electronic or hard copy format.
<http://emaillink.jpmorgan.com/t/AQ=AAMGjA/AAYLOg/QIFDJA/Ael/AOJAOJUBVk>
This email is confidential and subject to important disclaimers and conditi=ns including on offers for the
purchase or sale of securities, accuracy an= completeness of information, viruses, confidentiality, legal privilege, a=d
legal entity disclaimers, available at http://www.jpmorgan.com/pages/=isclosures/email
<http://www.jpmorgan.cogpages/disclosures/email> .
The information contained in this c=mmunication is confidential, may be attorney-client privileged, may constitute
inside information, and is intended only for the use of the a=dressee. It is the property of Jeffrey Epstein Unauthorized
use, di=closure or copying of this communication or any part thereof is strictl= prohibited and may be unlawful. If you
have received this communication in error, p=ease notify us immediately by return e-mail or by e-mail to
[email protected], =nd destroy this communication and all copies thereof, including all attachm=nts. copyright -all
rights reserved
6
EFTA_R1_01742405
EFTA02572702
Technical Artifacts (30)
View in Artifacts BrowserEmail addresses, URLs, phone numbers, and other technical indicators extracted from this document.
Domain
emaillink.jornorgan.comDomain
www.jpmorganmarkets.comEmail
[email protected]Email
[email protected]Phone
1-212) 834-5874Phone
1-800-477-0406Phone
1-800.477.0406Phone
1.800.477.0406Phone
2572697Phone
2572698Phone
2572699Phone
2572700Phone
2572701Phone
2572702Phone
477.0406URL
http://=maillink.jpmorgan.com/t/AO/AAMGjA/AAYLCIg/QIFDJA/Ael/ABlayiA/AQ/uY4eURL
http://=maillink.jpmorgan.com/t/AQ/AAMGjA/AAYLC/g/QIFDJA/Ael/A8QyhQ/AWGNvyURL
http://=maillink.jpmorgan.com/t/AQ/AAMGjA/AAYLOg/QIFDJA/Ael/ABuQqw/AQ/BEeuURL
http://=maillink.jpmorgan.com/t/AQ/AAMGjA/AAYUDg/QIF0JA/Ael/ABQyhg/AQ/Z+BIURL
http://emaillink.jpmorgan.com/t/AQ/AAMGjA/A=YLCIg/OJFDJA/Ael/ABPpLw/AQ/ND4rURL
http://emaillink.jpmorgan.com/t/AQ/AAMGjA/AAYLQg/OJFDJA/=el/gYc/AQ/D70DURL
http://emaillink.jpmorgan.com/t/AQ/AAMGjA=AAYLQg/QIFDJA/Ael/gYY/AQ/KSnlURL
http://emaillink.jpmorgan.com/t/AQ=AAMGjA/AAYLOg/QIFDJA/Ael/AOJAOJUBVkURL
http://emaillink.jpmorgan.com/t=AQ/AAMGjA/AAYLOg/O1FDJA/Ael/ABWWURL
http://rmaillinkjomorgan.com/t/AWAAMGjA/AAYMg/QIFDWAel/A8Qyhw/AQ/Ry8mURL
http://www.jpmorgan.cogpages/disclosures/emailURL
http://www.jpmorgan.com/pages/=isclosures/emailURL
https://mm.jpmorgan.com/disclosures/companyWire Ref
reflationWire Ref
reflectionRelated Documents (6)
DOJ Data Set 10OtherUnknown
EFTA01682184
186p
DOJ Data Set 10OtherUnknown
EFTA01370863
1p
Dept. of JusticeOtherUnknown
Medical Record/Clinical Encounter: DOJ-OGR-00026334
This clinical encounter document from the Bureau of Prisons details a medical evaluation of Jeffrey Epstein on July 12, 2019. It covers his medical history, current complaints, and treatment, including discussions around his triglyceride levels, sleep apnea, and back pain. The document was generated by the treating physician at the Metropolitan Correctional Center in New York.
1p
DOJ Data Set 8CorrespondenceUnknown
EFTA00014087
0p
DOJ Data Set 11OtherUnknown
EFTA02367961
1p
DOJ Data Set 10OtherUnknown
EFTA01977826
2p
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.